As a result, B-Raf-specific small molecule inhibitors (and eventually MEK inhibitors) were developed and found to dramatically improve patient prognosis, survival rate and lead to tumour regression through suppression of downstream ERK signalling [6–9]. This evidence concerns the gene BRAF and neoplasm.